Long-Acting PTH Prodrug Granted Orphan Drug Status for Hypoparathyroidism
The Company is investigating MBX 2109 in healthy adults in an ongoing phase 1 trial.
Hypoparathyroidism
Hypoparathyroidism Effectively Managed With TransCon PTH in Phase 3 Trial
The phase 3 PaTHway trial included 82 adults with chronic hypoparathyroidism.
Recall of All Doses of Parathyroid Hormone Natpara Issued
Takeda announced a voluntary recall of all doses of Natpara (parathyroid hormone) injection (25mcg, 50mcg, 75mcg, 100mcg) due to the possible presence of small rubber particulates in the Natpara cartridge originating from the rubber septum. Takeda is notifying healthcare professionals, patients, and specialty pharmacies regarding the recall. Natpara is supplied as a multiple-dose, dual-chamber glass…
Hypoparathyroidism Treatment Granted Orphan Drug Designation
TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore PTH to physiologic levels, normalizing blood and urinary calcium levels, serum phosphate levels and bone turnover.
